PTGX position history
The shares of Protagonist Therapeutics (PTGX) that FARALLON CAPITAL MANAGEMENT, L.L.C. reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 2,392,000 shares, $42M, 0.21% of portfolio
- 2021 Q4: 1,917,134 shares, $66M, 0.35% of portfolio, Reduce −19.9%
- 2022 Q1: 1,134,457 shares, $27M, 0.14% of portfolio, Reduce −40.8%
- 2022 Q2: 3,700,608 shares, $29M, 0.18% of portfolio, Add +226.2%
- 2022 Q3: 3,651,887 shares, $31M, 0.18% of portfolio, Reduce −1.3%
- 2022 Q4: 3,651,887 shares, $40M, 0.26% of portfolio
- 2023 Q1: 2,615,014 shares, $60M, 0.34% of portfolio, Reduce −28.4%
- 2023 Q2: 4,511,430 shares, $125M, 0.70% of portfolio, Add +72.5%
- 2023 Q3: 5,446,430 shares, $91M, 0.46% of portfolio, Add +20.7%
- 2023 Q4: 5,734,430 shares, $131M, 0.65% of portfolio, Add +5.3%
- 2024 Q1: 11,477,946 shares, $332M, 1.5% of portfolio, Add +100.2%
- 2024 Q2: 5,840,773 shares, $202M, 0.96% of portfolio, Reduce −49.1%
- 2024 Q3: 5,861,006 shares, $264M, 1.3% of portfolio, Add +0.3%
- 2024 Q4: 5,930,006 shares, $229M, 1.2% of portfolio, Add +1.2%
- 2025 Q1: 6,107,006 shares, $295M, 1.6% of portfolio, Add +3.0%
- 2025 Q2: 6,172,006 shares, $341M, 1.5% of portfolio, Add +1.1%
- 2025 Q3: 12,392,012 shares, $823M, 3.4% of portfolio, Add +100.8%
- 2025 Q4: 6,144,006 shares, $537M, 2.5% of portfolio, Reduce −50.4%
- 2026 Q1: 6,348,906 shares, $669M, 3.8% of portfolio, Add +3.3%
- 2026 Q2: 6,348,906 shares, $778M, 3.6% of portfolio
- 2026 Q3: 6,437,906 shares, $907M, 3.9% of portfolio, Add +1.4%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|